Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 11/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 11/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 1/20 | 1.00 |
| ▸ | CTSB | P07858 | 1/20 | 1.00 |
| ▸ | ELANE | P08246 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 0.82 |
| ▸ | AKT1 | P31749 | 2/20 | 0.75 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.75 |
| ▸ | RAB9A | P51151 | 1/20 | 0.74 |
| ▸ | PKM | P14618 | 3/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.73 |
| ▸ | APEX1 | P27695 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13212141 | 0.90 | KMT2A (1.00) | MEN1KMT2AKLKB1CTSBELANE | |
| SCHEMBL30209683 | 0.89 | KMT2A (0.80) | MEN1KMT2AKLKB1CTSBELANE | |
| SCHEMBL287025 | 0.86 | AKT1 (1.00) | MEN1KMT2AKLKB1CTSBELANE | |
| SCHEMBL5764160 | 0.85 | KMT2A (0.74) | MEN1KMT2AKLKB1CTSBELANE | |
| SCHEMBL11893078 | 0.85 | AKT1 (0.80) | MEN1KMT2AKLKB1CTSBELANE | |
| SCHEMBL13212131 | 0.84 | KMT2A (0.85) | MEN1KMT2AKLKB1CTSBELANE | |
| SCHEMBL14420797 | 0.83 | KMT2A (0.74) | MEN1KMT2AKLKB1CTSBELANE | |
| SCHEMBL3467548 | 0.81 | AKT1 (0.71) | MEN1KMT2AKLKB1CTSBELANE | |
| SCHEMBL14420720 | 0.81 | MEN1 (0.80) | MEN1KMT2AKLKB1CTSBELANE | |
| SCHEMBL31058614 | 0.81 | KMT2A (0.81) | MEN1KMT2APOLBAKT1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066614-A1 | Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB | 2007-03-22 | — | — | US | disclosed |
| US-7173030-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-20050009821-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009821-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | MEN1 942/4885KMT2A 3325/4885KLKB1 983/4885 |
| US-20070066614-A1 | Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD17B11 | MEN1 974/4885KMT2A 3281/4885KLKB1 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.